Hyperinsulinaemic hypoglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:22:20 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hyperinsulinaemic hypoglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Ersodetug for Patients with Uncontrolled Low Blood Sugar Due to Tumor-Related High Insulin Levels https://clinicaltrials.eu/trial/study-on-ersodetug-for-patients-with-uncontrolled-low-blood-sugar-due-to-tumor-related-high-insulin-levels/ Wed, 29 Apr 2026 15:06:09 +0000 https://clinicaltrials.eu/trial/study-on-ersodetug-for-patients-with-uncontrolled-low-blood-sugar-due-to-tumor-related-high-insulin-levels/ This study investigates tumor-associated hyperinsulinism (tumorHI), a condition where tumors cause excessive insulin production leading to low blood sugar levels (hypoglycemia). The condition can result from islet-cell tumors (insulinomas/proinsulinomas) or non-islet cell tumors. The purpose is to evaluate how effective and safe the medication ersodetug is when added to standard treatments for people whose hypoglycemia is not adequately controlled by current therapies.

The study is designed as a phase 3, randomized, double-blind trial comparing ersodetug to a placebo. Participants in the study have tumors that cause too much insulin to be released, resulting in dangerously low blood sugar levels that haven’t responded well to typical treatments. These individuals experience multiple episodes of severe hypoglycemia weekly, sometimes requiring assistance from others due to altered mental or physical status.

During the study, participants will receive either ersodetug or placebo while continuing their standard care treatments. Researchers will monitor how frequently participants experience low blood sugar events and how severe these events are. The study will track changes in hypoglycemic episodes and measure blood glucose levels through regular testing to determine if ersodetug helps reduce the frequency and severity of low blood sugar episodes.

]]> Study on the Effects of Pasireotide in Patients with Low Blood Sugar After Bariatric Surgery https://clinicaltrials.eu/trial/study-on-the-effects-of-pasireotide-in-patients-with-low-blood-sugar-after-bariatric-surgery/ Wed, 29 Apr 2026 14:29:30 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-pasireotide-in-patients-with-low-blood-sugar-after-bariatric-surgery/ This clinical trial is focused on studying a condition known as Post-Bariatric Hypoglycemia (PBH), which can occur in some individuals after they have undergone weight-loss surgery. This condition is characterized by low blood sugar levels after eating, which can lead to symptoms like dizziness, confusion, and even fainting. The study is testing a treatment called Pasireotide Diaspartate, which is a type of medication that mimics a natural hormone in the body to help control blood sugar levels. The medication is given as a solution for injection under the skin.

The purpose of the study is to evaluate how effective and safe Pasireotide Diaspartate is in managing blood sugar levels in patients with PBH. Participants in the study will receive either the medication or a placebo, which is an inactive substance, to compare the effects. The study will last for a period of 12 weeks, during which participants will be monitored for changes in their blood sugar levels and any side effects they may experience. The study aims to find the most effective dose of the medication that can help manage the symptoms of PBH.

Throughout the study, participants will undergo regular assessments to track their blood sugar levels and overall health. These assessments will help researchers understand how Pasireotide Diaspartate affects the body and its potential benefits for people with Post-Bariatric Hypoglycemia. The study is designed to provide valuable information that could lead to better treatment options for individuals experiencing this condition after bariatric surgery.

]]> Study on RZ358 for Treating Congenital Hyperinsulinism in Patients https://clinicaltrials.eu/trial/study-on-rz358-for-treating-congenital-hyperinsulinism-in-patients/ Wed, 29 Apr 2026 14:25:38 +0000 https://clinicaltrials.eu/trial/study-on-rz358-for-treating-congenital-hyperinsulinism-in-patients/ This clinical trial is focused on studying a condition known as , which causes low blood sugar levels, or , due to excessive insulin production. The trial will evaluate a treatment called , which is a type of medication known as a . This medication is designed to target and block the insulin receptor, potentially helping to manage blood sugar levels in patients with this condition. The study will also include a group for comparison.

The purpose of the study is to assess how effective and safe is in treating patients with . Participants in the study will receive the treatment through an , which means the medication will be administered directly into a vein. The study will last for a period of 24 weeks, during which the frequency of events will be monitored. This will help determine if can reduce the number of low blood sugar episodes experienced by patients.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This will include regular check-ups, blood tests, and other assessments to ensure the safety and well-being of all participants. The study aims to provide valuable information on the potential benefits of for individuals with and contribute to the development of new treatment options for this condition.

]]>